The Trial to Assess Chelation Therapy (TACT) presented ground breaking results in the diabetic sub study at the recent American Heart Association Meeting and published in Circulation. The paper, “The Effect of an EDTA-based Chelation Regimen on Patients With Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT).”

TACT was a $31 million, 10 year, double blind, randomized, placebo controlled, NIH sponsored, government study evaluating the efficacy and safety of chelation therapy in post MI patients over 50 years old. Patients received 40 infusions of EDTA chelation or placebo on top of standard medical therapy of aspirin, beta-blockers, ACEI, and statins. In the overall study (taking all participants together), the authors concluded: “Among stable patients with a history of MI, use of an intravenous chelation regimen with disodium EDTA, compared with placebo, modestly reduced the risk of adverse cardiovascular outcomes.”

But in those with diabetes (633 – 37%), there was an astounding 50% reduction in diabetic deaths and having a second MI was reduced by 52%. Additional improvements were also noted for significant reductions for stroke and for hospitalization from angina.

Also, patients who had a prior anterior MI showed an almost equal benefit to the diabetes group from chelation.

This is the first study of its kind and convincingly concludes that IV chelation provides a significant life prolonging benefit to specific groups of patients.

If you find this article interesting or helpful, please post it to your favorite page (see links above). If you think it may help someone you know and love, please share it with them. Contact our offices for more information or an appointment.

Live Well